Sheri D. Schully, Ph.D.
Knowledge Integration Team Lead, Office of the Associate Director
National Institutes of Health
National Cancer Institute
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
9609 Medical Center Drive, Rm. 4E106, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20852)
- Telephone: (240) 276-6936
- Fax: (240) 276-7921
- E-mail: email@example.com
- Using the tools of Knowledge Integration to uncover what is known or unknown about cancer epidemiology
- Translation of genome-based knowledge and technologies to improve population health and the use of biospecimens in research
- Ph.D. - Biological Sciences
Louisiana State University
- B.S. - Zoology, with a minor in Chemistry
Louisiana State University
Dr. Schully is Team Lead for the Knowledge Integration Team in the Epidemiology and Genomics Research Program's (EGRP) Office of the Associate Director. She was previously a Program Director in EGRP's Host Susceptibility Factors Branch. Dr. Schully's responsibilities include systematically managing the accumulating knowledge base and tools for cancer epidemiology and genomics to accelerate research, evidence-based recommendations, and translation into prevention and clinical practice. In addition, she manages a portfolio of grants related to factors that influence personal susceptibility to cancer, specifically genomic risks. Dr. Schully is also the Program Officer for the Breast and Colon Cancer Family Registries (CFRs) cohorts.
In addition to leading the Knowledge Integration team, Dr. Schully is heavily involved in Public Health Genomics research which is involves translating genomic discoveries into clinical care and to make a population health impact. She collaborates very closely with the Centers for Disease Control and Prevention's Office of Public Health Genomics. She is closely involved with the National Human Genome Research Institute's Clinical Genomics (CLinGen) Resource and Clinical Sequencing Exploratory Research (CSER) Program and serves on the steering committees of both groups.
Dr. Schully joined NCI in 2005 as a Presidential Management Fellow through which she completed several rotations in various NCI Divisions and Offices, including with EGRP, the Division of Cancer Epidemiology and Genetics (DCEG), and the Small Business Innovation Research Program within the Office of the Director. During these rotations, Dr. Schully worked with the Cancer Family Registries (CFRs) and organized activities for the Cancer Genetic Markers of Susceptibility Initiative. During her time as a Presidential Management Fellow, Dr. Schully also served as an intern with C-Change, a non-profit organization comprised of the nation's key cancer leaders from government, business, and non-profit sectors.
Clyne M, Schully SD, Dotson WD, Douglas MP, Gwinn M, Kolor K, Wulf A, Bowen MS, Khoury MJ. Horizon scanning for translational genomic research beyond bench to bedside. Genet Med. 2014 Jan 9 [Epub ahead of print].
Dotson WD, Douglas MP, Kolor K, Stewart AC, Bowen MS, Gwinn M, Wulf A, Anders HM, Chang CQ, Clyne M, Lam TK, Schully SD, Marrone M, Feero WG, Khoury MJ. Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin Pharmacol Ther. 2014 Apr;95(4):394-402.
Ioannidis JP, Zhou Y, Chang CQ, Schully SD, Khoury MJ, Freedman AN. Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. Ann Oncol. 2014 Jan;25(1):16-23.
Chang CQ, Yesupriya A, Rowell JL, Pimentel CB, Clyne M, Gwinn M, Khoury MJ, Wulf A, Schully SD. A systematic review of cancer GWAS and candidate gene meta-analyses reveals limited overlap but similar effect sizes. Eur J Hum Genet. 2014 Mar;22(3):402-8.
Ioannidis JP, Chang CQ, Lam TK, Schully SD, Khoury MJ. The geometric increase in meta-analyses from China in the genomic era. PLoS One. 2013 Jun 12;8(6):e65602.
Simonds NI, Khoury MJ, Schully SD, Armstrong K, Cohn WF, Fenstermacher DA, Ginsburg GS, Goddard KA, Knaus WA, Lyman GH, Ramsey SD, Xu J, Freedman AN. Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst. 2013 Jul 3;105(13):929-36.
Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle RT, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, Lauer MS, Meyerhardt JA, Olopade OI, Palmer JR, Sellers TA, Seminara D, Ransohoff DF, Rebbeck TR, Tourassi G, Winn DM, Zauber A, Schully SD. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):508-16.
Lam TK, Spitz M, Schully SD, Khoury MJ. "Drivers" of translational cancer epidemiology in the 21st century: needs and opportunities. Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):181-8.
Ioannidis JP, Schully SD, Lam TK, Khoury MJ. Knowledge integration in cancer: current landscape and future prospects. Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):3-10.
Khoury MJ, Coates RJ, Fennell ML, Glasgow RE, Scheuner MT, Schully SD, Williams MS, Clauser SB. Multilevel research and the challenges of implementing genomic medicine. J Natl Cancer Inst Monogr. 2012 May;2012(44):112-20.
Khoury MJ, Gwinn M, Dotson WD, Schully SD. Knowledge integration at the center of genomic medicine. Genet Med. 2012 Jul;14(7):643-7.
Goddard KA, Knaus WA, Whitlock E, Lyman GH, Feigelson HS, Schully SD, Ramsey S, Tunis S, Freedman AN, Khoury MJ, Veenstra DL. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med. 2012 Jul;14(7):633-42. Review.
Schully SD, Deverka PA, Ishibe N, Carlson JJ, Freedman A, Goddard KA, Khoury MJ, Ramsey SD. Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genet Med. 2012 Jul;14(7):656-62. Erratum in: Genet Med. 2013 Jan;15(1):91.
Schully SD, Benedicto CB, Khoury MJ. How can we stimulate translational research in cancer genomics beyond bench to bedside? Genet Med. 2012 Jan;14(1):169-70.
Ishibe N, Schully S, Freedman A, Ramsey SD. Use of Oncotype DX in Women with Node-Positive Breast Cancer. PLoS Curr. 2011 Jul 21;3:RRN1249.
Ishibe N, Carlson J, Ramsey SD, Freedman A, Schully S. Use of epidermal growth factor receptor mutation analysis in patients with advanced non-small-cell lung cancer to determine erlotinib use as first-line therapy. PLoS Curr. 2011 Jun21;3:RRN1245.
Schully SD, Yu W, McCallum V, Benedicto CB, Dong LM, Wulf A, Clyne M, Khoury MJ. Cancer GAMAdb: database of cancer genetic associations from meta-analyses and genome-wide association studies. Eur J Hum Genet. 2011 Aug;19(8):928-30.
Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ. Translational Research in Cancer Genetics: The Road Less Travelled. Public Health Genomics: 2011;14(1):1-8. Epub 2009 Dec 29.
Khoury MJ, McBride CM, Schully SD, Ioannidis JPA, Feero WG, Janssens AC, Gwinn M et al. The Scientific Foundation for Personal Genomics: Recommendations from an NIH-CDC Multidisciplinary Workshop. Genet Med: 2009;11(8):559-67.